You are here: Home » 2025 » December » Archives for 8th

Mavenir Confirms Refocus Strategy on Mobile Core and AI Vision With Expanded Leadership Team to Accelerate AI-Native Network Strategy

RICHARDSON, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) — Mavenir, the software company building AI–by–design mobile networks, today announced a strong leadership team to accelerate its vision for telco–first, cloud–native, AI–by–design networks. This transformation follows the company’s recent recapitalization and aligns with a refreshed product strategy focused on mobile core, AI–enabled automation, and cloud–native platforms.

New Operating Model Aligned to Strategic Priorities

Successful investment in AI will start with an AI–integrated approach, targeted deployments that solve specific problems with low risk, low disruption, and steady rewards. But it must go beyond using AI as a capability in isolation to augment existing processes. Crucially, it’s about building systems, from day one, to be part of a bigger AI vision of agentic, intent–driven operations, with intelligence everywhere.

Mavenir’s AI roadmap marks the transition from AI–integrated to AI–native networks, a shift that redefines how operators run and monetize their infrastructure. AI–integrated networks apply AI to specific functions, while AI–native networks embed intelligence into the core architecture, enabling full automation, real–time optimization, and industrial–scale monetization.

To streamline execution and advance its AI–integrated to AI–native network roadmap, Mavenir is realigning into two integrated business segments, both with a shared focus on AI automation:

  • Packet core, messaging, security
  • Voice, radio access technologies

Supported by platform & cloud technologies and business solutions.

This structure brings clearer accountability, sharper customer focus, and faster execution across product lines and R&D.

Strong Senior Leadership Team

As part of the new operating model, Mavenir is appointing several seasoned leaders to key roles effective immediately:

  • Uli Dopfer,
    Executive Vice President & Chief Financial Officer (CFO)
    Brings over 20 years of financial leadership, most recently as CFO of ADTRAN Holdings. Uli will oversee corporate finance, financial operations, long–term strategic planning and Human Resources.
  • Dejan Leskaroski,
    Executive Vice President & Chief Revenue Officer (CRO)
    Previously leading Mavenir’s strategic mobile core engagements and product lifecycle management. Dejan will define and drive Mavenir’s global revenue strategy and commercial growth.
  • Michael Cooper,
    Executive Vice President & General Manager, Packet Core, Security & Messaging
    Building on Michael’s proven leadership in driving growth for the packet core business unit, his role now expands to encompass packet core, security, and messaging businesses, while also taking on additional responsibility for Mavenir’s Digital Enablement (MDE) R&D.
  • Santhosh Kumar,
    Executive Vice President & General Manager, Platform & Cloud
    Following a tenure since 2008 marked by leadership in global IMS and messaging deployments and in platform engineering across the RAN and IMS portfolios. In this role, Santhosh will lead Platform Engineering, Center of Delivery (COD), and global product support with a mandate to advance platform consistency, accelerate cloud transformation, and scale operational efficiency across the company.
  • Sachin Karkala,
    Executive Vice President & General Manager, IMS & RAN
    A Mavenir leader for over 18 years, Sachin has driven cloud‑native and AI transformations, advanced network solutions, and large‑scale Open RAN deployments while pioneering innovations in IMS/VoLTE and Wi‑Fi calling. He now assumes the role of EVP & General Manager, IMS & RAN, where he will lead voice and radio access technologies with a mandate to accelerate AI‑native evolution, strengthen R&D performance, and deliver next‑generation solutions for global operators.
  • Sandeep Singh,
    Senior Vice President & General Manager, Business Solutions
    Sandeep will be responsible for product marketing across Mavenir’s entire product portfolio. In addition to this expanded role, Sandeep will retain his GM responsibilities for the Digital Enablement (MDE) Business Unit, continuing to drive innovation and growth in business support systems.

Mavenir’s senior leadership team remains strong and collaborative, with Pardeep Kohli (President & CEO), Bejoy Pankajakshan (EVP & Chief Technology & Strategy Officer), BG Kumar (President of Global Operations, Sales Operations & SCMP), Chuck Gilbert (EVP & Chief Legal Officer), Brandon Larson (SVP & GM, Cloud, AI & IMS Business Strategy), and Ilia Abramov (VP & GM, Security) continuing in their current roles. Their steadfast leadership and partnership will provide continuity and support as they work closely with the newly appointed executives to accelerate innovation, strengthen customer focus, and deliver Mavenir’s AI–native network vision.

Leadership Transitions

The company also announces that Terry Hungle, Executive Vice President and Chief Financial Officer; Bahram Jalalizadeh, Executive Vice President and Head of Sales and Marketing; Ashok Khuntia, President of Core Networks; and Anup Mahajan, Senior Vice President of Engineering, will transition from their roles at the end of January 2026. The company extends heartfelt gratitude for their contributions, leadership, and dedication that have shaped Mavenir’s success. Terry will continue as Special Advisor to the Board, and Bahram will remain engaged as a consultant to support ongoing customer programs.

Accelerating Innovation and Customer Value

“Mavenir was the first to deliver cloud–native products and have over 300+ operators serving ~3.5B subscribers. As our customers embrace AI–native networks, we are evolving our operating model to respond with greater speed and clarity,” said Pardeep Kohli, President and CEO. “We are excited to welcome these exceptional leaders to Mavenir. With a strong team and sharper strategic focus, we are well–positioned to deliver innovation and exceptional value for our customers.”

“Mavenir’s commitment to delivering AI–by–design solutions goes hand–in–hand with strengthening relationships with our key customers in mobile core,” said Hubert de Pesquidoux, Executive Chairman and Executive Partner at Siris. “This expanded leadership team brings the expertise necessary to drive our profitable growth agenda and reinforce our position as an industry leader. We look forward to accelerating innovation and delivering sustainable value for all stakeholders.”

Looking Ahead

With a unified operating model, a renewed strategic roadmap, and expanded leadership capacity, Mavenir is positioning itself to lead the industry’s transition from AI–integrated to AI–native networks, delivering the automation, intelligence, and agility operators require in the next era of telecom evolution.

About Mavenir 

Mavenir is enabling intelligent, automated, programmable networks through the development of telco–first, cloud–native, AI–by–design software solutions for mobile operators. The company’s deep telco domain expertise has been proven through deployments with 300+ operators globally in over 120 countries, which together serve more than 50% of the world’s subscribers. Mavenir combines its deep telco experience with the cloud and IT expertise and data science skillsets essential to solving real customer challenges. Its proven software solutions are AI by design, delivering the AI–native future and operators’ evolution to TechCos.

For more information, please visit www.mavenir.com

Mavenir PR Contacts:

Emmanuela Spiteri
[email protected]


GLOBENEWSWIRE (Distribution ID 9598380)

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

  • REC–4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)
  • After 12 weeks off therapy (week 25 of the study), 82% of evaluable patients (9 of 11) maintained a durable reduction in total polyp burden, with a 53% median reduction observed from baseline
  • Natural history analysis showed that 87% of untreated FAP patients – who resembled the inclusion criteria of TUPELO – had annualized polyp–burden increase, 10% remained stable, and 3% showed modest decrease—underscoring the disease’s progressive trajectory (n=55)
  • 40% of patients (4 out of 10) achieved a ≥1–point improvement in Spigelman stage—a clinically meaningful measure of upper GI disease severity to assess surveillance and clinical management
  • REC–4881 (4 mg QD) has a safety profile consistent with MEK1/2 inhibition, with the majority of treatment–related adverse events being Grade 1 or 2, Grade 3 events occurring in 15.8% of the safety–evaluable patients, and no Grade ≥4 TRAEs reported to date
  • First clinical validation of the Recursion OS, demonstrating how unbiased phenotypic and mechanistic insights—such as MEK1/2 rescue of APC loss–of–function—can translate to novel, differentiated therapeutics for diseases like FAP with no approved therapy and high prevalence of >50,000 patients in US and EU5
  • Next steps: Engage the FDA in the 1H26 to define a potential registration pathway, and in parallel, expand the population from ≥55 to ≥18 years old, and further optimize dosing schedule

SALT LAKE CITY, Dec. 08, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a clinical–stage TechBio company decoding biology to radically improve lives, today announced positive Phase 1b/2 data from the ongoing TUPELO trial of REC–4881, an investigational allosteric MEK1/2 inhibitor for familial adenomatous polyposis (FAP).

Through an unbiased phenotypic screen of thousands of compounds, the earliest version of the Recursion OS identified selective MEK1/2 inhibition as a highly specific mechanism capable of reversing APC loss–of–function signatures. Using high–content cellular phenomics driven by AI, REC–4881 emerged as one of the strongest phenotypic rescue hits, reverting APC–deficient cells toward a healthy state and suppressing ERK/MAPK hyperactivation downstream of APC loss. Guided by this AI–driven insight, Recursion in–licensed REC–4881 from Takeda and redirected REC–4881—originally evaluated clinically in solid tumors—as a mechanistically aligned therapeutic candidate for FAP. REC–4881 is now the first MEK1/2 inhibitor ever studied clinically for this disease.

“The durable polyp burden reduction demonstrated by REC–4881—especially the sustained effect seen at Week 25, 12 weeks after completing therapy—is highly encouraging for the FAP community,” said Jessica Stout, D.O., Assistant Clinical Professor, University of Utah School of Medicine, and Principal Investigator of the TUPELO study. “Given the near–100% lifetime risk of colorectal cancer and the absence of any approved medical therapies, patients today often face a lifetime of intensive surveillance and life–altering surgeries. These Phase 2 results provide a meaningful basis for hope and support the potential for REC–4881 to offer a much–needed non–surgical option for this debilitating, life–long disease.”

“These Phase 2 results mark a meaningful validation of the Recursion OS,” said Chris Gibson, Ph.D., Co–Founder and CEO of Recursion. “An unbiased phenotypic insight from our platform and driven by AI—linking MEK1/2 inhibition to APC loss–of–function biology—has now translated into rapid, substantial, and durable reductions in polyp burden in patients. This is a powerful example of how even the earliest versions of the Recursion OS can uncover therapeutic opportunities in diseases with no approved pharmacotherapy options. And since this discovery, we’ve only added to the breadth, depth, and power of the Recursion OS; we believe this is the first of many potential medicines that will advance as our flywheel of discovery accelerates.”

In the Phase 2 portion of the study, REC–4881 demonstrated rapid and durable reductions in polyp burden, with 43% median reduction in evaluable patients after 12 weeks of treatment. 75% of evaluable patients had a reduction in polyp burden in this same period. Importantly, the effect persisted well beyond the dosing period: 82% of evaluable patients (9 of 11) maintained reductions at Week 25—12 weeks after stopping therapy—with a 53% median decrease from baseline. These results are especially meaningful when considered alongside real–world natural history analyses showing that untreated FAP patients are expected to experience increases when left untreated.

“This program reflects a full validation cycle of the Recursion OS: an unbiased phenotypic signal identifying MEK1/2 inhibition as a rescue mechanism for APC loss–of–function, followed by mechanistic confirmation, clinical translation, and now encouraging human data in a disease with no approved medical therapies,” said Najat Khan, Ph.D., Chief R&D and Commercial Officer and incoming President and CEO. “REC–4881, an allosteric MEK1/2 inhibitor, represents a first precision–medicine approach for the causal biology of FAP. In TUPELO, we are seeing rapid, substantial, and durable reductions in polyp burden — including sustained benefit after patients stop therapy. Equally important, our ClinTech and real–world data capabilities have been instrumental in guiding this program — from refining eligibility to contextualizing a single–arm dataset with a first–of–its–kind natural history study.”

About FAP

FAP is one of the most clinically significant hereditary colorectal cancer syndromes and is caused by inactivating mutations in the APC gene, leading to the growth of hundreds to thousands of gastrointestinal polyps and a near 100% risk of developing colorectal cancer before the age of 40 if left untreated. With no approved pharmacotherapies, excisions followed sequentially by debilitating, life altering surgeries remain the only option to remove polyps and polyp burdened organs, typically involving colectomy in the early 20s. While this procedure removes immediate colon cancer risk, it does not address the underlying disease biology and does not prevent future polyp formation. Patients will continue to develop polyps in the rectum or upper GI tract, with approximately 50% of patients requiring subsequent life–altering surgical procedures to manage the persistent disease. Current treatment approaches lead to substantial long–term loss of quality of life, affecting continence, fertility, and long–term gastrointestinal function in relatively young patients. Approximately 90% of FAP patients go on to develop duodenal adenomas, with 6% eventually undergoing a high–morbidity risk duodenectomy to control polyp growth. FAP affects an estimated >50,000 individuals across the US and EU5 (France, Germany, Italy, Spain, and the UK).

Background on REC–4881 and Recursion’s Platform Insights

REC–4881 was discovered using one of the earliest versions of the Recursion OS (v0.1), through an unbiased, high–content AI–driven phenotypic screening approach in APC–deficient human cell models. Because FAP is driven by loss–of–function mutations in the APC gene, the platform was designed to identify molecules capable of rescuing APC–dependent biology—guided entirely by cellular phenotype, without presupposing any specific mechanism. Using AI/ML to extract and compare over a thousand morphological features that distinguish “diseased” from “healthy” states, the Recursion OS screened numerous investigative compounds and identified REC–4881 as one of the most robust phenotype–rescuing hits. In follow–up assays, REC–4881 consistently reverted APC–deficient cells toward a healthy–state phenotype and demonstrated potent, selective, and concentration–dependent MEK1/2 inhibition that was not seen across hundreds of other oncogenes and tumor suppressor models tested.

Importantly, the Recursion OS highlighted MEK1/2 inhibition as a mechanistic strategy to exploit a therapeutic vulnerability arising from APC loss in FAP—a disease area where MEK1/2 inhibition had not previously been investigated as a therapeutic strategy in a clinical setting. Based on this novel insight, Recursion in–licensed REC–4881 from Takeda, where it had been evaluated in solid tumors, and redirected it as the first MEK1/2 inhibitor advanced clinically for FAP. This program represents the power of a phenotype–first AI–driven discovery model: the platform surfaced a mechanistically aligned therapeutic opportunity solely through scaled high–dimensional exploration.

Today, the Company is using the Recursion OS 2.0 platform—including proprietary ClinTech capabilities of large–scale real–world evidence (RWE) analytics—to further advance the REC–4881 program. This includes a comprehensive natural history collaboration with Amsterdam University Medical Center, home to one of the largest and longest–running FAP registries, as well as analysis of more than 1,000 US FAP patients and 250,000 physician notes processed through Recursion’s custom LLM–based pipeline. Together, these data reinforce the relentlessly progressive nature of FAP, highlight the absence of spontaneous polyp regression, and demonstrate the substantial burden of repeated polyp–removal procedures and major surgeries experienced by real–world patients.

ClinTech insights also helped refine the design of the ongoing TUPELO trial, including expanding age eligibility from ≥55 to ≥18. This expansion was based on a thorough risk–benefit analysis, enabling evaluation of REC–4881 in younger patients who represent a substantial portion of FAP patients. REC–4881 has received Fast Track and Orphan Drug designations from the US FDA, as well as Orphan Drug designation from the European Commission.

Results of the Phase 2 Data for Ongoing REC–4881 Trial

Efficacy and Durability Findings

As of the November 25, 2025 data cutoff in the open–label Phase 2 portion of TUPELO, treatment with REC–4881 (4 mg QD) demonstrated meaningful and durable reductions in polyp burden in patients with FAP.

Week 13 Assessment

  • REC–4881 produced a median 43% reduction in total polyp burden among 12 efficacy–evaluable patients.
  • The majority of evaluable patients responded, with 75% showing reductions in polyp burden after 12 weeks of therapy.
  • 40% of patients (4 out of 10) achieved a ≥1–point improvement in Spigelman stage—a clinically meaningful measure of upper GI disease severity to assess surveillance and clinical management.
  • Other investigational agents currently under evaluation in separate studies generated approximately 17–29% median reduction in polyp burden after 12 months of treatment; no off–treatment durability was reported (Biodexa press release, June 24 2024)

Figure 1: Waterfall plot showing percent change from baseline in total polyp burden at Week 13 for efficacy–evaluable patients receiving REC–4881 (4 mg QD)

Week 25 Assessment

  • After 12 weeks of treatment, patients went off treatment for an additional 12–weeks. Durability of effect was maintained during the off–treatment observation period with 82% of patients responding (>0% reduction; 9 out of 11) at Week 25.
  • 73% achieved durable ≥30% reductions in polyp burden with a 53% median reduction in total polyp burden observed.
  • 40% of patients (4 out of 10) maintained a ≥1–point improvement in Spigelman stage from baseline.

Figure 2: Waterfall plot showing percent change from baseline in total polyp burden at Week 25 for efficacy–evaluable patients receiving REC–4881 (4 mg QD)

Safety Summary

As of the data cutoff, treatment with 4 mg REC–4881 demonstrated a safety profile generally consistent with prior MEK1/2 inhibitors.

  • Across the combined Phase 1b and Phase 2 safety cohorts (n=19), 94.7% of patients reported at least one treatment–related adverse event (TRAE), the majority of which were Grade 1/2 in severity. The most frequent TRAEs (≥10%) included: dermatitis acneiform / rash and blood CPK increase.
  • Grade 3 TRAEs occurred in 15.8% of patients; no Grade ≥4 TRAEs have been reported to date.
  • Treatment modifications were infrequent, with 2 of 19 patients experiencing dose interruption.

Figure 3: Summary of adverse events across Phase 1b and Phase 2 of the TUPELO trial

About the TUPELO Trial Design and Expanded Population
The Phase 1b/2 TUPELO trial is evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of REC–4881 monotherapy in patients with familial adenomatous polyposis (FAP).

Study Design and Analysis

Efficacy is assessed via upper and lower endoscopy at baseline, Week 13 (on–treatment), and Week 25 (off–treatment).

  • The primary endpoint is percent change from baseline in polyp burden, which is the sum of all polyp diameters in the GI.
  • The Efficacy Evaluable Population includes patients with measurable disease at baseline who received ≥75% of study drug and had at least one post–baseline endoscopic assessment. Disease staging uses the Spigelman system for upper GI polyposis and the InSiGHT classification for the lower GI tract.

Natural History Analyses
To better understand the natural history of FAP and to contextualize the single–arm efficacy of REC–4881, we collaborated with Amsterdam University Medical Center to analyze a registry of ~200 patients with FAP. 55 of these patients met the key inclusion criteria of TUPELO. We also leveraged our clinical development technology (ClinTech) platform to analyze US electronic health records (EHR), including physician notes, of ~1,000 FAP patients to assess disease progression and treatment patterns in the US. Both studies revealed high patient burden and progressive natural history of the disease. Results of the studies suggest that the natural history of FAP is to progress with relentless precancerous polyp progression: 87% of untreated patients in the registry experienced annualized increase in polyp burden. 10% were stable and 3% experienced a modest decrease in polyp burden. Mean increase of 60% and median increase of 28% in annualized polyp burden was observed. At least 75% of patients in the US EHR database had a major invasive surgery along with frequent polypectomies during follow–up.

Next Steps
Recursion plans to expand the population from ≥55 to ≥18 years old and further optimize dosing schedule. In parallel, the Company intends to engage the FDA in 1H26 to define a potential registration pathway.

Forward Looking Statements
This document contains information that includes or is based upon “forward–looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding Recursion’s anticipated engagement with the FDA; the clinical relevance of the TUPELO trial data and obtaining additional confirmatory data; advancing potential transformational therapies for FAP and beyond; subsequent REC–4881 studies, including expanded enrollment and alternate dosing schedule, and their results and advancing Recursion’s REC–4881 program further; the size of the potential FAP patient population; Recursion OS and other technologies potential and advancement of the future of medicine; business and financial plans and performance; and all other statements that are not historical facts. Forward–looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10–K and Quarterly Reports on Form 10–Q. All forward–looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine–learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine. Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New York, London, and the Oxford area. Learn more at www.recursion.com, or connect on X and LinkedIn.

Media Contact
[email protected]
Investor Contact
[email protected]

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/90547447–2b14–4969–a01f–353dfb0791aa
https://www.globenewswire.com/NewsRoom/AttachmentNg/057c1c25–0ed9–49f4–9e4b–2a7d3c9a234b
https://www.globenewswire.com/NewsRoom/AttachmentNg/b18bfe03–6a45–4ab5–bbe5–cfa957b1ad67


GLOBENEWSWIRE (Distribution ID 9598312)

Central Pattana تتعاون مع هيئة السياحة التايلاندية (TAT) و The Walt Disney (Thailand) لإطلاق Magical Festivities Land في تايلاند، لنشر أجواء عيد الميلاد في فعالية احتفالية مستلهمة من عالم Disney الساحر

بانكوك, Dec. 08, 2025 (GLOBE NEWSWIRE) —

تتعاون شركة Central Pattana plc، الشركة الرائدة في تطوير العقارات المستدامة في تايلاند والمشغّلة الرئيسة لمرلكز التسوق تحت علامة Central على مستوى البلاد، مع هيئة السياحة التايلاندية (TAT) وشركة The Walt Disney (Thailand)  لاستثمار ما يزيد عن 800 مليون بات تايلاندي لإطلاق فعالية احتفالية عالمية بمناسبة نهاية العام تحت عنوان: The Magical Stars. يسلّط هذا الاستعراض المبهر الضوء على أربعة ممالك مستوحاة من عالم الخيال وقصص ديزني الأيقونية، تُقام في مراكز التسوق Central في مختلف أنحاء البلاد، التي ستتزين بشجرة عيد الميلاد المميزة، إلى جانب مجسّمين لشخصيتي Disney المحبوبتين Mickey Mouse و Minnie Mouse بطول 3 أمتار، يرتديان ملابس مصنوعة من الحرير التايلاندي ضمن فعالية Disney The Magical Stars 2026  في centralwOrld. كما ستستضيف مراكز التسوق ركناً للألعاب والتسلية بعنوان Magic Town مستوحى من شخصيات Mickey & Friends ،  وMagic Castle  المستوحى من قصور أميرات Disney. تهدف هذه الحملة إلى تنشيط اقتصاد تايلاند وتعزيز السياحة وإنفاق المستهلكين من خلال استراتيجية “اقتصاد المهرجانات” (Festival Economy)، ونشر أجواء السعادة والاحتفالات في مختلف مراكز التسوق Central على مستوى البلاد، بما في ذلك مراكز Central  في أبرز الوجهات السياحية مثل centralwOrld Bangkok، و Central Phuket، و Central Pattaya، و Central Chiangmai وغيرها. سارعوا للمشاركة في أنشطة مهرجان The Magical Stars الذي سينشر أجواء البهجة والمرح اعتباراً من 14 نوفمبر 2025 إلى 11 يناير 2026.

وتسعى Central Pattana من خلال هذه المبادرة إلى تسليط الضوء على جمال الفن والثقافة التايلاندية من خلال فعالية The Magical Thai pride، التي تعرض مجموعة متنوعة من أشجار عيد الميلاد ذات الهويات التايلاندية، والمصنوعة على أيدي الحرفيين المحليين من جميع أنحاء البلاد، تكريماً لصاحبة الجلالة الملكة سيريكيت، الملكة الأم، ولمواصلة إرثها في الارتقاء بمستوى الحرف التايلاندية على الساحة العالمية.

في إطار هذه الحملة، تتعاونCentral  مع نخبة من الشركاء الرائدين، بما في ذلك هيئة السياحة التايلاندية (Tourism Authority of Thailand)، وشركة The Walt Disney Thailand، وCentral The1 Credit Card، وGeneral Card Services، وشركة AEON Thana Sinsap، وBangkok Bank، وCard X، و Siam Commercial Bank. تضم قائمة الشركاء أيضاً كلاً من Government Savings Bank، و Kasikorn Bank، و Krungsri Ayudhya Card، و Krungthai Bank، و Krungthai Card، و TTB Credit Card، و TMB Credit Card، و Thanachart Credit Card، وUOB Credit Card.

لهذا الموسم أيضاً، ستصل الاحتفالات إلى مستويات غير مسبوقة في مراكز التسوق centralwOrld، مع أكبر حديقة ألعاب ترفيهية خارج Disney في آسيا، تمتد على مساحة تزيد عن 3،500 متر مربع. وسيقدم مهرجان Disney The Magical Stars 2026  سبع مساحات للتجارب الغامرة، مصمّمة لمنح الزوار تجربة عيش المغامرات عن قرب، بما في ذلك ركن ألعاب الشتاء والثلجMickey & Friends ، Toy Story، Zootopia، Stitch، وFrozen، فضلاً عن بناء يحاكي الحقيقة لقصر أميرات Disney. وبمناسبة الذكرى العشرين لإنشاء Hong Kong Disneyland، ستجدون مجسّماً قابلاً للنفخ Mickey بطول 5 أمتار يرتدي زياً محدود الإصدار، ومجسّماً طبق الأصل لقوس هونج كونج. تُقام هذه الاحتفالات في 24 من مراكز التسوق Central، ويمكن للزوار الاستمتاع بالأنشطة والمرح في ركن Magic Town مع Mickey & Friends في أجواء احتفالية مفعمة بالمرح والإثارة.

كما يمكن للمتسوّقين في جميع مراكز التسوّق Central الاستمتاع بامتيازات احتفالية خاصة. في حين سيحصل المسافرون الدوليون الذين ينُفقون نحو 6،000 بات تايلاندي أو أكثر على حقيبة توت Good Goods Tote Bag كهديّة مجانية. تُطبق الشروط والأحكام.

جهة الاتصال: [email protected]


GLOBENEWSWIRE (Distribution ID 1001143674)

Farmers Earn While Reviving Native Forests Through a Blockchain-Powered App

Caroline Awuor tends to tree seedlings on her farm in Siaya County, Western Kenya. She is a beneficiary of the My Farm Trees Project. Credit: Jackson Okata/IPS

Caroline Awuor tends to tree seedlings on her farm in Siaya County, Western Kenya. She is a beneficiary of the My Farm Trees Project. Credit: Jackson Okata/IPS

By Jackson Okata
SIAYA, Kenya , Dec 8 2025 – For years, Morris Onyango had been trying to reforest his degraded land on the shores of River Nzoia, in Siaya county, 430 kilometers from Kenya’s Capital, Nairobi. But every time he planted trees on his farm, his efforts bore little fruit, as floodwaters would not only wash away his tree seedlings but also fertile topsoil on his land.

“The land became unproductive and bare. I tried reclaiming the land through reforestation, but the trees’ survival rate was too low,” Onyango said.

Siaya County has a 5.23 percent forest cover and is ranked 44th out of Kenya’s 47 counties. Judy Ogeche, a scientist from the Kenya Forestry Research Institute (KEFRI), says that the compromised forest and tree cover in the county and the lack of any gazetted forests have discouraged the integration of tree and crop farming.

“Communities here do not see tree growing as a lucrative venture. Some myths and beliefs discourage tree growing. For example, some people believe that growing the Terminalia mentalis (often known as the Panga Uzazi) tree attracts death,” says Ogeche.

According to Ogeche, another challenge is gender inequality in land ownership, with men owning most available land and making decisions on what should be planted.

“We have many women interested in restoring tree cover, but their husbands would not allow it,” Ogeche said.

Across Africa, reforestation projects struggle to survive beyond the seedling stage. However, in parts of Kenya, a groundbreaking digital innovation is transforming the landscape by empowering rural farmers to earn a living while restoring degraded lands with native trees.

Tech and Reforestation

In a bid to restore lost biodiversity and enhance tree cover in Kenya, Alliance Bioversity International and CIAT, in partnership with the International Union for Conservation of Nature (IUCN), launched the My Farm Trees project, a blockchain-based platform that offers guidance to subsistence farmers on seed selection, planting, and post-plant care, ensuring that seedlings survive and thrive in harsh conditions.

Implemented in the counties of Siaya, Turkana and Laikipia, MFT emphasizes genetically robust native species that support biodiversity, improve soil health, and provide long-term ecological and economic benefits.

Ogeche observes that the My Farm Trees project has motivated communities in Siaya to grow trees.

“They are given free seedlings and taught how to plant and take care of them, and when the trees grow, they are paid,” she said.

To provide the right seedlings, the project is partnering with the Kenya Forestry Research Institute (KEFRI), the Kenya Forest Services (KFS) and private tree nursery operators in the respective counties.

For farmers like Onyango, the My Farm Trees Project gave them the much-needed solution to their degraded lands and soils

“The project gifted me 175 seedlings of various trees, which I planted along the riverbank. The trees have helped me reclaim my land, prevent erosion and get paid for taking care of my own trees,” Onyango says.

How it Works

In the My Farm Trees project, participating farmers are registered on the MyGeo Farm App, which allows them to monitor seedlings from planting to growing. Through the app, farmers can track and report progress.

Francis Oduor, the National Project Coordinator, says since its rollout, the project has seen over 1,300 farmers registered on the MyGeo Tree App, and over 100,000 seedlings have been planted across the three counties.

“The project is especially interested in using indigenous trees for landscape restoration, which are native to specific areas, and to enhance genetic diversity,” says Oduor.

Oduor explains that My Farm Trees uses monitoring, verification, and incentives to empower local communities to become leaders and stewards of tree-planting projects that provide immediate short-term benefits.

“The project does not just focus on payment to farmers but the long-term benefits of restored landscapes for improved agricultural productivity, water regulation, and climate resilience,” said Oduor.

To ensure the use of native varieties and guarantee the production of quality tree seedlings, the project team collaborates with KEFRI to provide technical assistance to local tree nursery operators.

Lawrence Ogoda, a tree nursery operator, is among the project beneficiaries. He has been trained on seed collection, raising seedlings and record keeping.

“Through the MyGeo Tree and MyGeo Nursery Apps, I can collect data and track progress on seed collection, propagation and development at the nurseries.”

Before joining the My Farm Trees project, Caroline Awuor had not given much attention to growing trees. She received 110 seedlings, 104 of which have successfully survived and are earning her cash incentives.

“Most of them are fruit trees, including mangoes, avocado and jackfruit, while there are also some timber trees. In addition to the incentives from the project, I also earn money by selling the fruit,” she says.

Caroline intends to plant an additional 1,000 tree seedlings on her land, strategically located near the River Nzoia.

According to Joshua Schneck, the Green Climate Fund (GCF) Portfolio Manager for Global Programs at IUCN, My Farm Trees is an innovative project driven towards sustainable transformation.

The Impact

In Kenya, My Farm Tree has supported 3,404 farmers, 56 percent of whom are women. A total of 210,520 trees have been planted, with a survival rate of over 60 percent beyond the first year, with 1,250 hectares of land being restored across Siaya, Turkana, and Laikipia counties.

The program has released KES 26 million (approximately USD 200,000) in digital payments, directly benefiting 1,517 farmers. Additionally, 13 local nurseries have been strengthened in partnership with the Kenya Forestry Research Institute.

Also implemented in Cameroon, the project has seen the restoration of 1,403 hectares of forest land with over 145,000 seedlings being planted and 2,200 farmers registered on the platform. The project has also seen the restoration of 423 community lands and 315 sacred forests, with USD 130,000 in incentives distributed to farmers.

Oduor noted that the My Farm Trees project offers a scalable blueprint for  forest restoration by combining science and Blockchain technology in tree selection, post-planting support, and farmer incentives, which gives it  global relevance.

“MFT is a scalable model that aligns with climate action, poverty reduction, and ecosystem recovery. This approach supports the goals of the Paris Agreement, the United Nations Convention to Combat Desertification, and the UN Decade on Ecosystem Restoration,” Oduor said.
IPS UN Bureau Report

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);  

Bitget October 2025 Protection Fund Maintains $741M Average Despite Slumptober

VICTORIA, Seychelles, Dec. 08, 2025 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), today released its October 2025 Protection Fund report, recording an average monthly valuation of $741,435,710 despite a challenging month across digital asset markets. The fund peaked at $811,031,000 on October 6 and registered a monthly low of $691,886,000 on October 17, maintaining stability even as broader crypto prices declined.

October marked one of the more turbulent months for the industry this year, with major assets facing sharp corrections and heightened volatility. Against this backdrop, Bitget’s Protection Fund, established in 2022 with a base commitment of $300 million, continued to demonstrate resilience and transparency. The fund’s October average remains nearly 147% above its original allocation, reaffirming the UEX's capacity to safeguard user assets even in unpredictable conditions.

The Protection Fund provides an independently verifiable safety net designed to protect users during abnormal market events. Valuations are updated daily based on prevailing market conditions and asset holdings, ensuring full visibility into available coverage at any point in time.

Alongside the Protection Fund, Bitget’s Proof of Reserves (PoR) maintains a 1:1 reserve ratio or higher for all user assets. Together, the initiatives form a comprehensive protection framework with the PoR ensuring complete backing, while the Protection Fund offers an additional layer of defense during periods of extreme volatility.

“As we advance toward a borderless Universal Exchange, security and transparency must lead the way. A sustained Protection Fund above $700 million and being transparent in our Protection Fund numbers every month builds trust for users to engage with the market confidently, even in volatile conditions,” said Gracy Chen, CEO at Bitget.

October’s report reflects a market environment where users increasingly look for verifiable safeguards, not just performance. As global participation grows, consistent Protection Fund reserves help set expectations around incident response and recovery, forming part of Bitget’s long–term approach to user safety within the UEX architecture.

For real–time tracking, please visit Protection Fund here.

About Bitget

Established in 2018, Bitget is the world's largest Universal Exchange (UEX), serving over 120 million users with access to millions of crypto tokens, tokenized stocks, ETFs, and other real–world assets, while offering real–time access to Bitcoin price, Ethereum price, XRP price and other cryptocurrency prices, all on a single platform. The ecosystem is committed to helping users trade smarter with its AI–powered trading tools, interoperability across tokens on Bitcoin, Ethereum, Solana, and BNB Chain, and wider access to real–world assets. On the decentralized side, Bitget Wallet runs as the leading non–custodial crypto wallet supporting 130+ blockchains and millions of tokens. It offers multi–chain trading, staking, payments, and direct access to 20,000+ DApps, with advanced swaps and market insights built–in the platform.

Bitget is driving crypto adoption through strategic partnerships, such as its role as the Official Crypto Partner of the World's Top Football League, LALIGA, in EASTERN, SEA and LATAM markets. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. In the world of motorsports, Bitget is the exclusive cryptocurrency exchange partner of MotoGP™, one of the world’s most thrilling championships.

For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet

For media inquiries, please contact: [email protected]

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/613267e9–a67c–4ac3–8cf2–8cfa6608fd20
https://www.globenewswire.com/NewsRoom/AttachmentNg/247fe204–ea93–404f–9a5e–bb856c1c6462


GLOBENEWSWIRE (Distribution ID 1001143658)

Earth Rover Program تنطلق عالمياً بالتزامن مع فعاليات اليوم العالمي للتربة، وتكشف النقاب عن تطبيق Soilsmology العلمي الجديد

لندن, Dec. 08, 2025 (GLOBE NEWSWIRE) —  تنطلق Earth Rover Program اليوم حول العالم وتكشف عن مفهوم “soilsmology “ الثوري – وهو تطبيق مبتكر في مجال علم الزلازل يقدّم رؤية غير مسبوقة حول صحة وبنية التربة، التي تعدّ من النظم البيئية الحيوية الأهم والأضعف على وجه الأرض. يهدف برنامج المنظمة، التي أشرف على تطويرها صندوق Bezos Earth Fund، إلى توفير القدرة على مراقبة صحة التربة وقياسها وتوفير بيانات قابلة للتطبيق تتيح اتخاذ الإجراءات التصحيحية المناسبة على نطاق واسع. يساهم هذا النهج في تعزيز إدارة التربة بشكل أكثر ذكاءً وفعالية على مستوى العالم، ويدعم الجهود الرامية إلى منع الانهيار المناخي والبيئي.

يعتمد بقاء كوكبنا على الصلة الثمينة بالتربة، التي تدعم انتاج ما نسبته 99 في المائة من الغذاء البشري، كما تعدّ واحدة من أكبر مستودعات الكربون على سطح الأرض، إذ تخزن كميات من الكربون تفوق ما يوجد في الغلاف الجوي وجميع النباتات الأرضية مجتمعة. ومع ذلك، تشير التقديرات إلى مستويات حرجة من التدهور في تربة الأراضي على مستوى العالم تصل إلى 75 في المائة، ما يشكّل تهديداً على الأمن الغذائي والتنوع البيولوجي واستقرار المناخ. تقليدياً، كانت مراقبة صحة التربة وفحصها عملية مكلفة وبطيئة، تتطلّب أخذ عينات التربة بشكل يدوي. إلا أن Earth Rover Program قلبت الموازين وسمحت باستخدام علم الزلازل بطرق مبتكرة، لتوفير “رؤية” دقيقة للطبقات الضحلة من التربة عن طريق إرسال موجات عالية التردد عبر الأرض. تتيح هذه التقنية تقييم مجموعة واسعة من الخصائص، مثل حجم التربة، والكثافة الظاهرية والرطوبة، والتركيبة الداخلية دون الحاجة إلى الحفر – وهي جميعها مؤشرات أساسية على صحة التربة.

على مدار عامين، تطوّر البرنامج من نموذج أولي لإثبات الفكرة إلى شبكة عالمية فعالة. وتُظهر النتائج المبكرة أن التحليل الزلزالي قادر على توفير دقة مكانية عالية للغاية تصل إلى 10 سنتيمترات، تتيح التمييز بين النظم البيئية المختلفة وأنماط الزراعة المتباينة. وقد أنتجت التجهيزات الميدانية المماثلة الموزّعة في أوروبا وأفريقيا وأمريكا الجنوبية بيانات متّسقة عالية الجودة وقابلة للمقارنة، ما يثبت موثوقية استخدام هذه المنهجية عبر بيئات متنوعة.

شكّلت التكلفة الميسورة لهذه التقنية من أبرز الاختراقات التي تحققت في هذا المشروع. فمن خلال تطوير جيل جديد من مقاييس التسارع التي تعتمد على تقنية الأنظمة الكهروميكانيكية الدقيقة ( MEMS)، نجح فريق العمل في تقليل تكلفة أجهزة الاستشعار من 1,000 دولار في 2023 إلى 10 دولارات فقط حالياً، مع استهداف الوصول إلى دولار واحد. تهدف هذه التكلفة المنخفضة إلى تمكين جميع المزارعين، بما في ذلك أولئك الذين يعملون في المجتمعات الأكثر فقراً، من الاستفادة من التقنيات السريعة لتقييم صحة التربة دون الحاجة إلى الحفر. هذا ويتمثل الهدف بعيد المدى في إنشاء شبكة مجتمعية عالمية لرصد حالة التربة، يقوم في إطارها المستخدمون بمشاركة بياناتهم عبر منصّات مفتوحة المصدر ومشفّرة، لوضع خريطة عالمية مشتركة وموثوقة لأحوال التربة – على غرار مشروع الجينوم البشري – لفهم بنية التربة تحت سطح الأرض.”

تحقق Earth Rover Program حالياً تقدّماً ملحوظاً على عدد من الابتكارات، أبرزها دمج استخدام علم الزلازل مع مستشعر جديد ونموذج استشعار قائم على الذكاء الاصطناعي لمراقبة صحة التربة بسرعة وعلى نطاق واسع؛ توسيع نطاق رسم الخرائط الزلزالية لقياس رطوبة التربة العميقة؛ وقياس المسامية المتصلة؛ وتحديد خصائص التربة، مثل القوام ومستوى الكربون. تشكّل هذه المؤشرات عوامل أساسية لفهم دور التربة في تحسين مرونة المحاصيل، والتقاط وتخزين الكربون، وتنظيم الاستخدام المستدام والعادل لموارد المياه.

يستخدم البرنامج تقنيات غير تدخّلية لتحليل ودراسة التربة، بخلاف الطرق التقليدية مثل رفع العينات عبر الحفر، أو الحفر العميق، ما يتيح جمع البيانات بطريقة أسرع وعلى نطاق أوسع وبتكلفة منخفضة. من شأن هذا النهج أن يفتح آفاقاً جديدة أمام المزارعين الراغبين في تقليل استخدام الأسمدة والري والحراثة العميقة، دون التأثير على المحاصيل. هذا ويتمّ حالياً تنفيذ عدد من المشاريع التجريبية مع شركاء في المملكة المتحدة وكينيا وكولومبيا وألمانيا وفرنسا، بما يتيح إرساء الأساس لقاعدة بيانات عالمية للتربة.

ولضمان الاستفادة العملية من بيانات التربة المعقدة، حرصت Earth Rover Program على تطوير منصة ERP–GPT، وهي منصة ذكاء اصطناعي تمّ تصميمها لتحويل نتائج القياس إلى إرشادات ونصائح واضحة وقابلة للتطبيق لصالح المزارعين والعلماء وواضعي السياسات. وتهدف المنظمة على المدى الطويل إلى إنشاء أول نظام عالمي للتنبؤ بأحوال التربة، أو ما يُعرف بـ”soilcast“، لتوفير رؤى تنبؤية مماثلة لنموذج التنبؤ بحالة الطقس، وبالتالي دعم التخطيط طويل الأمد لاستخدام الأراضي.

وفي هذا السياق، قال George Monbiot، المؤسس المشارك لمنظمة Earth Rover Program:
“لطالما كانت التربة بمثابة عالم غامض بالنسبة لنا. وعلى الرغم من الجهود التي دأب علماء التربة على بذلها، بقي فهمنا لأسرارها محدوداً وغير كامل. إلا أن Earth Rover Program استطاعت تغيير هذه المعادلة، من خلال توفير فهم أعمق لخصائص التربة وعيوبها، لتمكين المزارعين من تقليل الأضرار البيئية مع الحفاظ على إنتاجية المحاصيل. ونحن نأمل أن يساهم هذا النهج مع الوقت في دعم ابتكار وسائل بيولوجية جديدة لتحسين صحة التربة، ما يسمح لنا بإطعام العالم دون الإضرار بكوكب الأرض.”

من جانبه، قال الدكتور Andy Jarvis، مدير تحالف مستقبل الغذاء التابع لصندوق Bezos Earth Fund:
“الجميع يدرك مدى صعوبة الحفر في التربة لمعرفة وفهم ما يحدث تحت السطح. لكن فريقEarth Rover Program وجد طريقة لدراسة هذا العالم الخفي دون الإضرار به. فالمعرفة الأفضل بالتربة تساهم بحماية كل ما نهتم به، مثل المناخ والطبيعة.”

وتابعت البروفسورة Jacqueline Hannam من University of Greenwich:
“من الصعب للغاية أن نتمكن من فهم ما يحدث تحت سطح الأرض، لأن التربة تتكوّن من طبقات عدة، غير منظورة للعين. توفر Earth Rover Program إمكانات هائلة لقياس الخصائص الرئيسية للتربة، مثل العمق، والكثافة الحجمية، وحركة تدفق المياه تحت السطح، دون الحاجة إلى الحفر. يمثّل هذا الإنجاز تقدّماً ضرورياً وملحّاً لمنع التدهور المستمر للتربة ودعم الإدارة المستدامة لها.” 

ستُصدر Earth Rover Program تقريرها الافتتاحي بعنوان “Soilsmology: Transforming our Understanding of Soil” أو “علم التربة: تغيير فهمنا لأحوال التربة” خلال ندوة افتراضية عبر الإنترنت في 5 ديسمبر 2025. تتضمن الندوة كلمة افتتاحية لـ Kate Raworth  وحلقة نقاش مع المؤسسين المشاركين والبروفسورة Franciska de Vries.

ملاحظات للمحررين

تعدّ Earth Rover Program منظمة بحثية عالمية غير ربحية تركز على دراسات التربة والبيئة، تعاون على تأسيسها صحفي بيئي وعالم زلازل وعالم تربة. يتألف فريقها البحثي من 17 عضواً ويضمّ استاذين اثنين و15 متخصّصاً حائزاً على دكتوراه يمثّلون تسع دول. كما تتعاون المنظمة مع مؤسسات رائدة في المملكة المتحدة وكينيا وكولومبيا، وتحظى بدعم من صندوق Bezos Earth Fund ومؤسسة UBS Optimus Foundation.

جهات الاتصال:
اتصالات وسائل الإعلام
Austyn Close, Atalant
[email protected] / +44 7850421012

يمكنكم الاطلاع على الملف المتاح بصيغة “بيه دي إف” والمرفق بهذا البيان الصحفي عبر الرابط الالكتروني التالي: https://ml–eu.globenewswire.com/Resource/Download/79424530–57f4–48ba–93bb–b87e081b1507


GLOBENEWSWIRE (Distribution ID 1001143596)

Lancement mondial du programme Earth Rover à l'occasion de la Journée mondiale des sols Dévoilement du concept scientifique de « soilsmology »

LONDRES, 08 déc. 2025 (GLOBE NEWSWIRE) — Earth Rover Program est lancé aujourd’hui à l’échelle mondiale, introduisant « Soilsmology » — une nouvelle application de la sismologie qui offre une fenêtre sans précédent sur la santé et la structure des sols, l’un des écosystèmes les plus essentiels et les plus vulnérables de la planète. Développé avec le soutien du Bezos Earth Fund, le programme vise à rendre la santé des sols visible, mesurable et exploitable à grande échelle, transformant la gestion mondiale des terres et soutenant les efforts destinés à prévenir l’effondrement climatique et écologique.

Les sols soutiennent 99 % de la production alimentaire humaine et stockent plus de carbone que l’atmosphère et la végétation réunies. Pourtant, 75 % des sols mondiaux sont dégradés, menaçant la sécurité alimentaire, la biodiversité et la stabilité du climat. Jusqu’à présent, le suivi de la santé des sols était coûteux, lent et dépendait d’échantillonnages invasifs. Earth Rover utilise la sismologie d’une manière nouvelle pour « voir » dans les couches superficielles du sol en envoyant des ondes ultra–haute fréquence à travers le terrain. Ces techniques révèlent des propriétés telles que le volume du sol, la densité apparente, l’humidité et la structure interne — autant d’indicateurs essentiels de la santé des sols.

En deux ans, le programme est passé d’une preuve de concept à un réseau mondial opérationnel. Les premiers résultats montrent que l’analyse sismique peut offrir une résolution spatiale exceptionnellement fine (environ 10 cm) et distinguer différents écosystèmes et systèmes agricoles. Des configurations de terrain identiques déployées en Europe, en Afrique et en Amérique du Sud ont produit de manière constante des données de haute qualité et comparables.

Une avancée majeure réside dans l’accessibilité financière. En développant un accéléromètre MEMS de nouvelle génération, l’équipe a réduit le coût des capteurs, passant de 1 000 $ en 2023 à seulement 10 $ aujourd’hui, avec un objectif de 1 $. Cette réduction spectaculaire vise à rendre l’évaluation rapide et non invasive des sols accessible à tous les agriculteurs, y compris ceux des communautés les plus pauvres. L’objectif est de créer un réseau mondial de science citoyenne dédié aux sols, où les utilisateurs contribuent à des données via des plateformes open source et chiffrées, afin de produire une carte mondiale partagée et fiable des sols — une sorte de Projet Génome Humain (Human Genome) pour le sol sous nos pieds.

Earth Rover Program fait désormais progresser plusieurs innovations : l’intégration de la sismologie avec un nouveau design de capteur et un modèle d’IA pour un suivi rapide et évolutif de la santé des sols ; l’expansion de la cartographie sismique de l’humidité des sols en profondeur ; la mesure de la porosité connectée ; ainsi que la détermination de la texture du sol et de son contenu en carbone. Ces indicateurs s’avèrent essentiels pour comprendre le rôle du sol concernant la résilience des cultures, le stockage du carbone et la régulation de l’eau.

Les méthodes du programme évitent de perturber les sols — contrairement aux techniques traditionnelles de carottage et de creusement de fosses — tout en offrant une collecte de données plus rapide, moins coûteuse et plus facilement extensible. Cela ouvre de nouvelles possibilités pour les agriculteurs souhaitant réduire l’usage d’engrais, l’irrigation et le labourage profond sans diminuer les rendements. Des projets pilotes sont en cours avec des partenaires au Royaume–Uni, au Kenya, en Colombie, en Allemagne et en France, constituant la base d’une base de données mondiale.

Pour garantir que les données complexes sur les sols puissent être exploitées, le programme a également développé ERP–GPT, une plateforme d’IA conçue pour traduire les mesures en recommandations claires pour les agriculteurs, les scientifiques et les décideurs. À long terme, Earth Rover Program vise à créer la première prévision des sols au monde — ou « soilcast » — offrant des informations prédictives comparables aux prévisions météorologiques et permettant de soutenir la planification de l’utilisation des terres sur le long terme.

George Monbiot, cofondateur d’Earth Rover Program, a déclaré : « Cela fait bien trop longtemps que les sols demeurent un territoire obscur pour nous. Malgré les avancées majeures réalisées par les scientifiques du sol, notre compréhension reste morcelée et insuffisante. Earth Rover Program vient bouleverser cet état de fait. Grâce à une connaissance plus fine et plus nuancée des qualités, des limites et des besoins de leurs sols, les agriculteurs pourront réduire leur impact sur l’environnement tout en préservant – voire en améliorant – leurs rendements. À terme, nous espérons que cette approche favorisera l’émergence de nouvelles méthodes biologiques de restauration des sols, ouvrant la voie à une agriculture capable de nourrir la population mondiale sans continuer à épuiser la planète ».

Pour sa part, le Dr Andy Jarvis, Directeur de Future of Food au Bezos Earth Fund, a souligné : « Quiconque a déjà creusé une fosse dans le sol sait combien il est difficile de saisir ce qui se passe sous la surface. L’équipe d’Earth Rover Program a découvert une manière d’explorer ce monde caché sans le perturber ni le détruire. Une connaissance approfondie des sols renforce tous les aspects qui nous tiennent à cœur en matière de climat et de protection de la nature, ouvrant la voie à des pratiques agricoles plus durables et respectueuses de l’environnement ».

La professeure Jacqueline Hannam, de l’Université de Greenwich, a commenté : « Comprendre ce qui se passe sous nos pieds reste un véritable défi. Les méthodes développées par Earth Rover Program offrent un potentiel considérable pour mesurer avec précision des propriétés essentielles du sol, telles que sa profondeur, sa densité apparente et la circulation de l’eau — et ce, sans jamais perturber le sol avec une pelle. Cette percée est à la fois cruciale et urgente : elle pourrait inverser la dégradation des sols et permettre une gestion durable, mieux informée et respectueuse de l’environnement ».

Earth Rover Program publiera son rapport inaugural, Soilsmology : Transformer notre compréhension des sols, lors d’un webinaire virtuel le 5 décembre 2025, avec des remarques d’ouverture de Kate Raworth et un panel réunissant les cofondateurs du programme et la professeure Franciska de Vries.

Notes aux rédacteurs :

Earth Rover Program est une organisation mondiale de recherche à but non lucratif, fondée par un journaliste environnemental, un sismologue et un spécialiste des sols. Son équipe de recherche, composée de 17 membres, inclut deux professeurs et 15 docteurs (PhD) originaires de neuf pays. L’organisation collabore avec des institutions pionnières au Royaume–Uni, au Kenya et en Colombie et bénéficie du soutien du Bezos Earth Fund et de la UBS Optimus Foundation.

Contact presse :

Austyn Close, Atalanta
[email protected] / +44 7850 421012

Un PDF accompagnant cette annonce est disponible à l’adresse suivante : https://ml–eu.globenewswire.com/Resource/Download/79424530–57f4–48ba–93bb–b87e081b1507


GLOBENEWSWIRE (Distribution ID 1001143596)

O Earth Rover Program é lançado globalmente no Dia Mundial do Solo e revela o conceito científico de “Soilsmology”

LONDRES, Dec. 08, 2025 (GLOBE NEWSWIRE) — O Earth Rover Program é lançado globalmente hoje, apresentando a “soilsmology” – uma nova aplicação da sismologia que abre uma janela sem precedentes para a saúde e estrutura do solo, um dos ecossistemas mais vitais e vulneráveis do planeta. Desenvolvido com o apoio do Bezos Earth Fund, o programa visa tornar a saúde do solo visível, mensurável e acionável em escala, transformando a gestão global da terra e apoiando os esforços para prevenir o colapso climático e ecológico.

O solo sustenta 99% da produção de alimentos humanos e armazena mais carbono do que a atmosfera e a vegetação combinadas. No entanto, 75% dos solos do mundo estão degradados, ameaçando a segurança alimentar, a biodiversidade e a estabilidade climática. Até agora, o monitoramento da saúde do solo tem sido caro, lento e dependente de amostragem invasiva. O Earth Rover Program usa a sismologia de novas maneiras para “ver” as camadas superficiais do solo, enviando ondas de ultra–alta frequência através do solo. Essas técnicas revelam propriedades como volume do solo, densidade aparente, umidade e estrutura interna – todos eles são indicadores–chave da saúde do solo.

Ao longo de dois anos, o programa evoluiu de uma prova de conceito para uma rede global em funcionamento. Os resultados iniciais mostram que a análise sísmica pode fornecer uma resolução espacial excepcionalmente fina (cerca de 10 cm) e distinguir diferentes ecossistemas e sistemas agrícolas. Configurações de campo idênticas implantadas na Europa, África e América do Sul produziram consistentemente dados comparáveis e de alta qualidade.

Um grande avanço reside na acessibilidade. Ao desenvolver um acelerômetro MEMS de última geração, a equipe reduziu os custos dos sensores de US$ 1.000 em 2023 para apenas US$ 10 hoje, com uma meta de US$ 1. Essa redução drástica visa tornar a avaliação rápida e não invasiva do solo acessível a todos os agricultores, incluindo aqueles nas comunidades mais pobres. O objetivo é uma rede global de ciência cidadã do solo, com usuários contribuindo com dados por meio de plataformas criptografadas de código aberto para criar um mapa global do solo compartilhado e confiável – semelhante a um Projeto Genoma Humano para o solo sob nossos pés.

O Earth Rover Program está agora avançando em várias inovações: integração da sismologia com um novo design de sensor e modelo de IA para monitoramento rápido e escalável da saúde do solo; expansão do mapeamento sísmico da umidade profunda do solo; medição da porosidade conectada; e determinação da textura e do carbono do solo. Esses indicadores são cruciais para entender o papel do solo na resiliência das culturas, no armazenamento de carbono e na regulação da água.

Os métodos do programa evitam perturbar o solo – ao contrário da amostragem tradicional e da abertura de poços – enquanto oferecem coleta de dados mais rápida, barata e escalável. Isso abre novas possibilidades para agricultores que buscam reduzir o uso de fertilizantes, irrigação e aração profunda sem reduzir as colheitas. Projetos–piloto estão em andamento com parceiros no Reino Unido, Quênia, Colômbia, Alemanha e França, formando a base de um banco de dados global.

Para garantir que dados complexos do solo possam ser transformados em ações, o programa também desenvolveu o ERP–GPT, uma plataforma de IA projetada para traduzir medições em orientações claras para agricultores, cientistas e formuladores de políticas. A longo prazo, o Earth Rover Program visa criar a primeira previsão do solo do mundo – ou “soilcast” – fornecendo insights preditivos comparáveis à previsão do tempo e apoiando o planejamento de uso da terra a longo prazo.

George Monbiot, cofundador do Earth Rover Program, disse:
“Por muito tempo, o solo tem sido obscuro para nós. Apesar do trabalho brilhante de cientistas do solo, nossa compreensão permanece incompleta. O Earth Rover Program muda isso. Com uma compreensão mais rica das qualidades e deficiências de seu solo, os agricultores podem reduzir os danos ambientais enquanto mantêm as colheitas. Com o tempo, esperamos que essa abordagem apoie novos métodos biológicos para a melhoria do solo, permitindo–nos alimentar o mundo sem devorar o planeta.”

Dr Andy Jarvis, Diretor de Futuro da Alimentação no Bezos Earth Fund, disse:
“Qualquer pessoa que tenha cavado um poço de solo sabe como é difícil entender o que está acontecendo abaixo da superfície. A equipe Earth Rover encontrou uma maneira de ler esse mundo oculto sem destruí–lo. Um melhor conhecimento do solo fortalece tudo o que nos importa no clima e na natureza.”

Professora Jacqueline Hannam, da Universidade de Greenwich, comentou:
“É realmente desafiador saber o que está acontecendo debaixo dos nossos pés. Os métodos do Earth Rover Program têm um potencial enorme para quantificar propriedades–chave do solo, como profundidade, densidade aparente e movimento da água – sem colocar uma pá no chão. Este avanço é urgentemente necessário para reverter a degradação do solo e apoiar a gestão sustentável.”

O Earth Rover Program lançará seu relatório inaugural, Soilsmology: Transformando nossa Compreensão do Solo, durante um webinar virtual em 5 de dezembro de 2025, com comentários de abertura de Kate Raworth e um painel com os cofundadores do programa e a Professora Franciska de Vries.

Notas aos editores

O Earth Rover Program é uma organização global de pesquisa sem fins lucrativos fundada por um jornalista ambiental, um sismólogo e um cientista do solo. Sua equipe de pesquisa de 17 membros inclui dois professores e 15 doutores de nove países. A organização faz parceria com instituições líderes no Reino Unido, Quênia e Colômbia e é apoiada pelo Bezos Earth Fund e pela UBS Optimus Foundation.

Contato com a imprensa:

Austyn Close, Atalanta

[email protected] / +44 7850421012

O PDF que acompanha este anúncio está disponível em https://ml–eu.globenewswire.com/Resource/Download/79424530–57f4–48ba–93bb–b87e081b1507


GLOBENEWSWIRE (Distribution ID 1001143596)

EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025


Christopher Potts, Chief Operating Officer & Chief Technology Officer, EBC Financial Group (UK) Ltd, representing EBC Financial Group to receive the Best Broker for Execution at the Professional Trader Awards 2025 by Holiston Media.

LONDON, Dec. 08, 2025 (GLOBE NEWSWIRE) — EBC Financial Group (“EBC”) has been named Best Broker for Execution at the Professional Trader Awards 2025, organised by Holiston Media. Now in its sixth year, the programme recognises excellence across 16 categories, with winners determined through a mix of nominations and trader voting.

“At the heart of EBC are trust and respect—values that translate into delivering exceptional service that respects the trade,” said David Barrett, CEO of EBC Financial Group (UK) Ltd. “For professional traders, execution is not just a feature; it is mission–critical. It shapes every aspect of a workflow, from decision–making to risk calibration. This award validates our investment in the infrastructure necessary to create the best possible trading environment.”

High Engagement Reflects Evolving Trader Priorities
Launched initially to spotlight brokers offering professional client accounts, the Professional Trader Awards have expanded to recognise the wider active trading community. Brokers participate in the awards process, and winners are determined by votes from professional, active or prop traders.

Barrett stated, “The voting process demonstrates which service elements traders themselves view as essential. It provides clear insight into how brokers are meeting the operational standards expected by experienced traders.” He added that for EBC Financial Group, being evaluated directly by market participants highlights the firm’s alignment with the high standards required by professional and active traders.

Execution Standards Take Centre Stage at Professional Trader Awards
Holiston Media announced winners across 16 categories, covering execution, trading analysis, account technology, performance tools, trading conditions, risk management, margin structures, education, loyalty initiatives and client relationship services. EBC Financial Group’s recognition in Best Broker for Execution reflects the critical importance of reliable execution for professional and active traders.

Barrett explained, “Execution quality influences every aspect of a trader’s workflow, from decision–making to risk calibration. Being evaluated through a trader–led voting process confirms that our services meet the level of reliability expected by the market.”

EBC’s Building Blocks to Deliver the Best Trading Environment
This recognition reinforces EBC’s commitment to maintaining the highest standards in execution and service as the firm continues to respond to the evolving needs of professional and active traders. EBC introduced a series of platform enhancements in 2025, including expanded multilingual support, smart liquidity routing, and performance upgrades that support execution speeds as low as 20ms. Its proprietary tools, such as the Trading Black Box and Private Room, enhance traders’ control over pricing and execution.

EBC’s recognition as Best Broker for Execution at the Professional Trader Awards 2025 is among the many accolades the platform has received. Other recognitions include the ‘Best CFD Provider’ at the 2025 Online Money Awards, as well as the Most Trusted Broker and Best Trading Platform at the 2025 World Finance Forex Awards.

For more information, visit www.ebc.com. 

Disclaimer: This material is for information only and does not constitute a recommendation or advice from EBC Financial Group and all its entities (“EBC”). Trading Forex and Contracts for Difference (CFDs) on margin carries a high level of risk and may not be suitable for all investors. Losses can exceed your deposits. Before trading, you should carefully consider your trading objectives, level of experience, and risk appetite, and consult an independent financial advisor if necessary. Statistics or past investment performance are not a guarantee of future performance. EBC is not liable for any damages arising from reliance on this information.

About EBC Financial Group
Founded in London’s esteemed financial district, EBC Financial Group (EBC) is a global brand known for its expertise in financial brokerage and asset management. Through its regulated entities operating across major financial jurisdictions—including the UK, Australia, the Cayman Islands, Mauritius, and others—EBC enables retail, professional, and institutional investors to access a wide range of global markets and trading opportunities, including currencies, commodities, shares, and indices. 

Recognised with multiple awards, EBC is committed to upholding ethical standards, and these subsidiaries are licensed and regulated within their respective jurisdictions. EBC Financial Group (UK) Limited is regulated by the UK’s Financial Conduct Authority (FCA); EBC Financial Group (Cayman) Limited is regulated by the Cayman Islands Monetary Authority (CIMA); EBC Financial Group (Australia) Pty Ltd, and EBC Asset Management Pty Ltd are regulated by Australia’s Securities and Investments Commission (ASIC); EBC Financial (MU) Ltd is authorised and regulated by the Financial Services Commission Mauritius (FSC); EBC Financial Group SA (Pty) Ltd is authorised and regulated by the Financial Sector Conduct Authority (FSCA).

At the core of EBC are a team of industry veterans with over 40 years of experience in major financial institutions. Having navigated key economic cycles from the Plaza Accord and 2015 Swiss franc crisis to the market upheavals of the COVID–19 pandemic. We foster a culture where integrity, respect, and client asset security are paramount, ensuring that every investor relationship is handled with the utmost seriousness it deserves.

As the Official Foreign Exchange Partner of FC Barcelona, EBC provides specialised services across Asia, LATAM, the Middle East, Africa, and Oceania. Through its partnership with United to Beat Malaria, the company contributes to global health initiatives. EBC also supports the ‘What Economists Really Do’ public engagement series by Oxford University’s Department of Economics, helping to demystify economics and its application to major societal challenges, fostering greater public understanding and dialogue.

https://www.ebc.com/ 

Media Contact: 

Susindhraseghar Chandrasekar
Global Public Relations Executive
[email protected]

Aldric Tinker Toyad
Global PR Lead
[email protected]

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/80e3ecd1–53ca–4763–afda–eb88550f18b1


GLOBENEWSWIRE (Distribution ID 9598385)

Selon de nouvelles données, les coûts des soins de santé privés rebattent les cartes pour les millionnaires qui envisagent une expatriation

LONDRES, 08 déc. 2025 (GLOBE NEWSWIRE) — Une forte accélération de la migration des fortunes à l’échelle mondiale en 2025 coïncide avec la divergence rapide des coûts des soins de santé privés dans le monde, faisant de la disponibilité et du coût de soins privés fiables un facteur décisif dans le choix du lieu de résidence, d’investissement et d’obtention des droits de résidence ou de citoyenneté pour les familles fortunées.

De nouvelles données publiées aujourd’hui par les leaders mondiaux de la planification de la citoyenneté et de la résidence, Henley & Partners, confirment la demande record de planification transfrontalière et mettent en évidence l’exposition aux coûts des soins de santé comme une importante « variable invisible » qui détermine les décisions de destination à long terme pour les familles candidates à l’expatriation dans le monde entier.

Une demande mondiale record redéfinit les priorités

Henley & Partners a reçu des dossiers représentant 92 nationalités cette année (2025) et a répondu à la demande de plus de 50 programmes de résidence et de citoyenneté. Au cours des cinq dernières années, le cabinet a aidé des candidats de 136 nationalités différentes, ce qui souligne l’ampleur et la diversité du mouvement migratoire actuel concernant les grandes fortunes. Pour les trois premiers trimestres de 2025, le cabinet a constaté une augmentation de 43 % des demandes par rapport à la même période en 2024, une indication claire que la mobilité transfrontalière augmente parmi les familles fortunées.

« La mobilité mondiale est désormais au cœur de la stratégie de gestion des risques des familles fortunées », constate le Dr. Christian H. Kaelin, Président de Henley & Partners. « Alors que les clients développent leur vie dans plusieurs juridictions, ils examinent non seulement l’accès à la résidence et à la citoyenneté, mais aussi le coût réel du maintien de ce style de vie, en particulier le prix d’un système de santé privé et fiable. Les destinations qui semblent intéressantes en théorie peuvent perdre de leur attrait une fois que l’exposition aux risques liés aux soins de santé est véritablement compris. »

Selon de nouvelles données, le coût des soins de santé devient un indicateur essentiel de la mobilité

Pour aider les clients à prendre leurs décisions en matière de destination, Henley & Partners se réfère à un indice récemment publié, le SIP Health Cost Index (HCI) 2025, une référence systématique du coût réel des soins de santé privés pour les individus et les familles en mobilité internationale dans 50 pays clés, sur la base des primes de l’assurance médicale privée internationale (IPMI). Henley & Partners occupe une position de leader en matière de planification de la résidence et de la citoyenneté, et cet indice apporte un éclairage complémentaire essentiel : le coût des soins de santé privés peut modifier sensiblement l’accessibilité et la pertinence à long terme d’une destination, en particulier pour les familles qui gèrent les besoins des enfants, des parents vieillissants ou les traitements électifs transfrontaliers.

« Les coûts des soins de santé privés augmentent partout dans le monde, mais à des rythmes et selon des schémas très différents. Les systèmes de soins de santé à deux vitesses, dans lesquels les soins de la plus haute qualité ne sont souvent accessibles qu’à ceux qui peuvent se le permettre financièrement et qui sont bien assurés, sont de plus en plus nombreux », remarque Kevin Buerchler, PDG de SIP Medical Family Office. Seul un nombre limité de pôles d’excellence en matière de soins de santé offre la qualité et l’accessibilité dont ont besoin les familles expatriées ; la gestion de la qualité et du coût des soins est par conséquent plus importante que jamais. »

Les destinations aux coûts les plus élevés, et celles où l’impact commence à se faire sentir

L’indice HCI confirme les leaders habituels en termes de coûts élevés. Les États–Unis se classent en effet comme le marché privé des soins de santé le plus cher au monde, avec des coûts annuels moyens basés sur l’IPMI de 17 969 USD par personne, suivis de Hong Kong (16 175 USD) et de Singapour (14 231 USD). Ces marchés constituent une base de référence élevée pour les primes d’assurance et le budget santé des ménages.

Cependant, les évolutions inattendues observées en dehors des centres traditionnels sont plus importants pour la planification de la relocalisation. Les pays émergents d’Asie sont entrés dans la catégorie des destinations à coûts élevés, la Chine, la Thaïlande et Taïwan figurant désormais parmi les douze marchés de soins privés les plus chers au monde. La forte demande auprès des hôpitaux internationaux haut de gamme et les voyages médicaux régionaux font grimper en flèche les coûts d’hospitalisation, même lorsque les soins ambulatoires de routine restent relativement peu coûteux, ce qui crée des surprises budgétaires importantes pour les familles qui s’installent à l’étranger.

Europe, Moyen–Orient et autres destinations à coût abordable

L’Europe présente l’un des écarts les plus importants en matière de coût des soins privés : le Royaume–Uni, la Grèce et l’Espagne figurent parmi les marchés les plus chers de la région, en raison notamment de la taxe sur les primes d’assurance au Royaume–Uni et en Grèce. La Suisse se situe en milieu de classement, ce qui montre que la réputation d’un pays comme destination coûteuse en matière de soins de santé ne se traduit pas toujours par la même exposition à l’IPMI pour les familles internationales.

Au Moyen–Orient, les Émirats arabes unis se classent au 10e rang mondial. Cette position reflète l’expansion rapide des infrastructures de soins de santé haut de gamme et les ambitions du tourisme médical. Ces destinations offrent ainsi un accès de grande qualité, mais avec des coûts élevés correspondants.

Pour les clients qui cherchent à concilier qualité et accessibilité, l’Afrique et une grande partie de l’Amérique latine restent des destinations relativement économiques. Le Maroc est le marché le moins cher au monde, avec 6 251 USD par an, tout comme d’autres pays à faible coût tels que la Roumanie, le Nigeria, l’Égypte, le Kenya et l’Afrique du Sud. Le Brésil, classé 7e au niveau mondial, constitue la principale exception. En effet, certaines destinations d’Amérique latine rivalisent désormais avec les marchés traditionnels à coûts élevés en matière de soins privés haut de gamme.

Les conséquences pour les millionnaires candidats à l’expatriation

Avec l’augmentation des volumes de migration des personnes fortunées, l’exposition au coût des soins de santé privés, autrefois envisagée a posteriori, devient un facteur important dans la stratégie de résidence et de citoyenneté. Le SIP Health Cost Index fournit aux familles candidates à l’expatriation et à leurs conseillers un outil de comparaison pratique pour anticiper les budgets de santé à long terme et éviter les pièges dissimulant des coûts élevés lors de la sélection d’un nouveau logement, d’une résidence secondaire ou d’un mode de vie reposant sur plusieurs points d’ancrage.

Contact pour les médias :

Sarah Nicklin
Responsable du groupe en charge des relations publiques
E–mail : [email protected]
Portable : +27 72 464 8965


GLOBENEWSWIRE (Distribution ID 1001143481)